Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1986-4-15
|
pubmed:abstractText |
It is currently recommended that venom immunotherapy (VIT) be continued as long as the sensitivity persists (indicated by positive venom skin tests or RAST). In this pilot study, we performed a retrospective survey of the clinical and immunologic effects of stopping VIT. The 82 patients studied had received maintenance VIT for a mean of 14 months and had stopped VIT a mean of 43 months before evaluation. Subsequent "field" stings in 28 patients caused systemic reactions in six cases (22%), which is significantly higher than the 1% to 3% systemic reaction rate in patients who remain on maintenance VIT. The 22% reaction rate is a minimal estimate caused by loss of venom sensitivity in some patients and residual venom-specific IgG antibody levels in others. Reevaluation of venom skin tests and IgG levels was possible in 43 patients. A tenfold decline from before VIT skin test results was observed in 27 patients (63%). Skin tests remained clearly positive in 32/43 (74%), became weakly positive in 9/43 (21%), and 2/43 (5%) became negative. The IgG level declined from typical maintenance levels before stopping VIT (mean 7.2 +/- 1.2 micrograms/ml) to levels typical of untreated patients at the time of retesting (mean 1.95 +/- 0.3 micrograms/ml). Despite the marked fall of IgG antibody, one third of the patients still had levels in the average range observed in patients receiving maintenance VIT. We conclude that there is a substantial risk of anaphylactic sting reaction if VIT is stopped while venom sensitivity persists.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0091-6749
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
77
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
435-42
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:3950251-Adult,
pubmed-meshheading:3950251-Aged,
pubmed-meshheading:3950251-Arthropod Venoms,
pubmed-meshheading:3950251-Female,
pubmed-meshheading:3950251-Humans,
pubmed-meshheading:3950251-Immunoglobulin G,
pubmed-meshheading:3950251-Immunotherapy,
pubmed-meshheading:3950251-Male,
pubmed-meshheading:3950251-Middle Aged,
pubmed-meshheading:3950251-Patient Compliance,
pubmed-meshheading:3950251-Patient Dropouts,
pubmed-meshheading:3950251-Skin Tests,
pubmed-meshheading:3950251-Time Factors
|
pubmed:year |
1986
|
pubmed:articleTitle |
Clinical and immunologic observations in patients who stop venom immunotherapy.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|